Army Lt. Col. Nathan McWhorter, chief of Nuclear Medicine, consults with patient, Harold G. Overstreet, retired Sgt. Maj. of the Marine Corps at Brooke Army Medical Center, Fort Sam Houston, Texas, Sept. 27, 2022. Overstreet is undergoing a new treatment for prostate cancer patients which is combined with a specific type of positron emission tomography (PET) imaging agent for prostate cancer. The PET imaging allows the doctor to see where the cancer is located as well as the extent of metastasis. The new FDA-approved prostate-specific membrane antigen (PSMA) PET imaging scan significantly
Army Lt. Col. Nathan McWhorter, chief of Nuclear Medicine, consults with patient, Harold G. Overstreet, retired Sgt. Maj. of the Marine Corps at Brooke Army Medical Center, Fort Sam Houston, Texas, Sept. 27, 2022. Overstreet is undergoing a new treatment for prostate cancer patients which is combined with a specific type of positron emission tomography (PET) imaging agent for prostate cancer. The PET imaging allows the doctor to see where the cancer is located as well as the extent of metastasis. The new FDA-approved prostate-specific membrane antigen (PSMA) PET imaging scan significantly improves prostate cancer detection and treatment.
Size: 6770px × 4518px
Photo credit: © Operation 2022 / Alamy / Afripics
License: Licensed
Model Released: No
Keywords: agency, army, brooke, cancer, center, defense, dha, health, medical, pet, prostate
